CDCynthia Demicheli

Cynthia Demicheli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cynthia Demicheli has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multivariate Optimization Applied to the Synthesis of Meglumine Antimoniate with Low Levels of Trivalent Antimony

    by Henrique Fabrino, Frédéric Frezard, Ana Carolina de Oliveira, Letícia Costa, Cynthia Demicheli

    Meglumine antimoniate (MA) is a pentavalent antimony (SbV) drug recommended for the treatment of leishmaniasis. It is known that the trivalent antimony (SbIII) present as a residue in MA contributes to the drug side effects. In this article, multivariate optimization was used in the synthesis of MA in order to obtain a drug with low levels of SbIII. Four variables (source of antimony, temperature, water volume and pH) were preliminarily evaluated by 24-1 fractional factorial design. Central composite design (CCD) was used to determine the optimal synthesis conditions, using two different sources of SbV and the significant variables selected in a fractional factorial design. Response surface methodology obtained by CCD provided a model with non-significant regression (p = 0.05) for the synthetic route via KSb(OH)6. On the other hand, synthetic route via SbCl5 reached minimum value of SbIII content of 0.172% and significant regression, and it was selected for further evaluations. The analysis of MA formulations synthesized with SbCl5 under optimized conditions revealed the efficiency of multivariate optimization to reduce SbIII content. In addition, the monitoring of some physicochemical parameters of these formulations maintained at 40 ºC for 90 days, showed that stability was not altered at 95% confidence level.

  • Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis

    by Erly G Azevedo, Raul R Ribeiro, Sydnei M da Silva, Cláudio S Ferreira, Ligia E de Souza, Adriel Af Ferreira, Renata A de Oliveira e Castro, Cynthia Demicheli, Simone A Rezende, Frédéric Frézard

    Test the hypothesis that pegylated meglumine antimoniate-containing liposomes (LMA) and their mixture with non-pegylated (conventional) LMA may be more effective than conventional LMA against visceral leishmaniasis (VL), because of wider drug distribution among different mononuclear phagocyte system (MPS) tissues. Sb was determined in the blood and MPS tissues after administration of pegylated or conventional LMA intravenously to mongrel dogs naturally infected with Leishmania infantum and Swiss mice. Pegylated and conventional LMA as well as their mixture were evaluated for their antileishmanial efficacy in BALB/c infected with L. infantum through determination of parasite load in liver, spleen and bone marrow. An improved targeting of Sb to the bone marrow of dogs was clearly evidenced, as an important impact of pegylation. In accordance with this data, pegylated LMA significantly reduced parasite load in bone marrow of infected mice, in contrast to conventional LMA. The mixed formulation of conventional and pegylated LMA promoted parasite suppression to a higher extent in both spleen and bone marrow, compared to pegylated or conventional LMA. The present work establishes for the first time the potential of mixed formulations of conventional and pegylated liposomes as a drug delivery strategy for improved treatment of VL.


  • Comparative studies of univariate and multivariate optimizations for manganese determination in antihypertensive drugs by electrothermal atomic absorption spectrometry

    by Josianne Nicácio Silveira, Paulo Celso Pereira Lara, Michelle Batista Dias, Clésia Cristina Nascentes, Cynthia Demicheli, José Bento Borba da Silva

    Comparative studies using the univariate and multivariate optimizations (factorial design) were undertaken to determine manganese in antihypertensive drugs by electrothermal atomic absorption spectrometry (ET AAS). For the univariate method, the optimum pyrolysis and atomization temperatures were 500 and 2200 °C, and for multivariate analysis, the temperatures were 500 and 2400 °C, respectively. No differences were observed between the methods with respect to the slopes of the calibration curves, recoveries, results for certified urine samples for the two levels, and the averages of the intra- and inter-assay coefficients of variation (CV) using Student t and F tests as a statistical tool (P < 0.05). Calibration was performed by matrix matching. All other studies were made using the optimized multivariate conditions. The characteristic mass was of 0.68 ± 0.17 pg (the recommended mass is 0.60 pg). The limits of detection and quantification were 0.23 and 0.77 µg L-1, respectively. Intra- and inter-assay studies on the drug spiked with 0.5, 1.0, and 1.5 µg L-1 of Mn yielded mean results of 3.6 ± 1.9% and 9.6 ± 2.2%, respectively. For the intra-assay evaluation, seven samples of each concentration were evaluated for Mn on the same day, whereas, for the inter-assay study, these solutions were analyzed in three replicates during three consecutive days. Recovery studies on the drug spiked with three levels of Mn (n = 7 for each level) furnished results between 101.4 ± 17.2% and 106.6 ± 7.5%. The results of a certified urine sample analysis (two levels of Mn) agreed at a 95% level of confidence. Forty eight antihy pertensive drug samples were analyzed, and the drug contents varied between 2.9 ng and 1.9 µg capsule-1.Key words: manganese, antihypertensive drugs, electrothermal atomic absorption spectrometry, multivariate optimization.